| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | QS11 | GDSC1000 | pan-cancer | AAC | 0.074 | 0.04 |
| mRNA | XMD8-92 | GDSC1000 | pan-cancer | AAC | -0.098 | 0.04 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.073 | 0.04 |
| mRNA | JNK-9L | GDSC1000 | pan-cancer | AAC | 0.071 | 0.04 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.065 | 0.04 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.1 | 0.04 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.098 | 0.04 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.07 | 0.04 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.05 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | 0.076 | 0.05 |